In light of this, TAS1R3 could be considered as a novel therapeutic target to treat ARDS, thus suggesting a wider role for this candidate in pulmonary-related symptoms in the context of SARS-CoV-2 infection [41]. Here, TAS1R3 is linked to acute respiratory distress syndrome.